SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/21/17 SOBR Safe, Inc. 10-Q 6/30/17 51:4.5M Discount Edgar/FA |
Document/Exhibit Description Pages Size 1: 10-Q Quarterly Report HTML 464K 2: EX-10.7 Form of Series A Preferred Stock Purchase HTML 51K Agreement 3: EX-10.8 Form of Amendment No. 1 to Series A Preferred HTML 24K Stock Purchase Agreement 4: EX-31.1 Certification -- §302 - SOA'02 HTML 22K 5: EX-31.2 Certification -- §302 - SOA'02 HTML 21K 6: EX-32.1 Certification -- §906 - SOA'02 HTML 17K 7: EX-32.2 Certification -- §906 - SOA'02 HTML 17K 14: R1 Document and Entity Information HTML 41K 15: R2 Condensed Consolidated Balance Sheets HTML 86K 16: R3 Condensed Consolidated Balance Sheets HTML 38K (Parenthetical) 17: R4 Condensed Consolidated Statements of Operations HTML 58K (Unaudited) 18: R5 Condensed Consolidated Statements of Cash Flows HTML 79K (Unaudited) 19: R6 Note 1. Organization, Operations and Summary of HTML 54K Significant Accounting Policies 20: R7 Note 2. Going Concern HTML 20K 21: R8 Note 3. Related Party Transactions HTML 24K 22: R9 Note 4. Notes Payable HTML 134K 23: R10 Note 5. Derivative Liability HTML 43K 24: R11 Note 6. Income Taxes HTML 20K 25: R12 Note 7. Stock Options and Subscriptions Payable HTML 198K 26: R13 Note 8. Common Stock HTML 26K 27: R14 Note 9. Commitments and Contingencies HTML 33K 28: R15 Note 1. Organization, Operations and Summary of HTML 80K Significant Accounting Policies (Policies) 29: R16 Note 1. Organization, Operations and Summary of HTML 33K Significant Accounting Policies (Tables) 30: R17 Note 4. Notes Payable (Tables) HTML 134K 31: R18 Note 6. Derivative Liability (Tables) HTML 31K 32: R19 Note 7. Stock Options and Subscriptions Payable HTML 180K (Tables) 33: R20 Note 9. Commitments and Contingencies (Tables) HTML 31K 34: R21 Note 1. Organization, Operations and Summary of HTML 26K Significant Accounting Policies (Details) 35: R22 Note 1. Organization, Operations and Summary of HTML 24K Significant Accounting Policies (Details Narrative) 36: R23 Note 2. Going Concern (Details Narrative) HTML 19K 37: R24 Note 3. Related Party Transactions (Details HTML 44K Narrative) 38: R25 Note 4. Notes Payable (Details) HTML 103K 39: R26 Note 4. Notes Payable (Details 1) HTML 32K 40: R27 Note 4. Notes Payable (Details Narrative) HTML 165K 41: R28 Note 5. Derivative Liability (Details ) HTML 30K 42: R29 Note 5. Derivative Liability (Details Narrative) HTML 58K 43: R30 Note 7. Stock Options and Subscriptions Payable HTML 46K (Details) 44: R31 Note 7. Stock Options and Subscriptions Payable HTML 252K (Details 1) 45: R32 Note 7. Stock Options and Subscriptions Payable HTML 90K (Details Narrative) 46: R33 Note 8. Common Stock (Details Narrative) HTML 34K 47: R34 Note 9. Commitments and Contingencies (Details) HTML 34K 48: R35 Note 9. Commitments and Contingencies (Details HTML 20K Narrative) 50: XML IDEA XML File -- Filing Summary XML 83K 49: EXCEL IDEA Workbook of Financial Reports XLSX 55K 8: EX-101.INS XBRL Instance -- imle-20170630 XML 2.06M 10: EX-101.CAL XBRL Calculations -- imle-20170630_cal XML 95K 11: EX-101.DEF XBRL Definitions -- imle-20170630_def XML 429K 12: EX-101.LAB XBRL Labels -- imle-20170630_lab XML 734K 13: EX-101.PRE XBRL Presentations -- imle-20170630_pre XML 560K 9: EX-101.SCH XBRL Schema -- imle-20170630 XSD 187K 51: ZIP XBRL Zipped Folder -- 0001477932-17-004113-xbrl Zip 95K
EXHIBIT 32.1
CERTIFICATION PURSUANT TO 18 USC, SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of TransBiotec, Inc. (the “Company”) on Form 10-Q for the quarter ended June 30, 2017, as filed with the Securities and Exchange Commission on or about the date hereof (the “Report”), I, Ivan Braiker, President of the Company, certify, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:
| (1) | The Report fully complies with the requirements of Sections 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|
|
|
| (2) | Information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Dated: August 16, 2017 | By: | /s/ Ivan Braiker |
|
|
| ||
| President |
|
A signed original of this written statement required by Section 906 has been provided to TransBiotec, Inc. and will be retained by TransBiotec, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.
This ‘10-Q’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed on: | 8/21/17 | |||
8/16/17 | ||||
For Period end: | 6/30/17 | NT 10-Q | ||
List all Filings |